RxDoctor Payments Data

Steve Hou, MD

Internal Medicine · Flushing, NYNPI 1245450204

Payments from drug & device makers

$11,261in general payments, 2019–2025

Across 396 payments — averaging $28.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$921
  • Boehringer Ingelheim$673
  • Merck$628
  • plus $4K from 23 others

What the payments were for

  • Food & beverage$11,09599%
  • Education$1661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,261 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$24,933
Medicare patients
48
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl611$234,034
JardianceEmpagliflozin174$146,606
Synjardy XrEmpagliflozin/Metformin Hcl91$79,543
VemlidyTenofovir Alafenamide52$73,195
JanuviaSitagliptin Phosphate80$70,343
OzempicSemaglutide34$48,159
JanumetSitagliptin Phos/Metformin Hcl57$41,545
EliquisApixaban52$39,424
FarxigaDapagliflozin Propanediol38$36,358
TradjentaLinagliptin52$34,334
ProliaDenosumab18$30,283
CreonLipase/Protease/Amylase17$28,402
RybelsusSemaglutide22$26,932
LinzessLinaclotide33$22,711
XareltoRivaroxaban28$21,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy$673$271,351335 claims
MerckJanuvia, Janumet, Janumet Xr$628$124,745159 claims
Novo NordiskOzempic, Rybelsus$433$75,09156 claims
GileadVemlidy$3,151$73,19552 claims
AbbVieCreon, Linzess, Ubrelvy$1,016$64,54863 claims
PfizerEliquis, Abrysvo$85$55,664109 claims
AstraZenecaFarxiga$1,051$36,35838 claims
AmgenProlia$453$30,28318 claims
Johnson & JohnsonXarelto$219$21,72328 claims
GSKShingrix, Arnuity Ellipta$94$19,04098 claims
BayerKerendia$458$16,36425 claims
Astellas Pharma US IncMyrbetriq$49$13,79223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →